⚡ Quick Start — If You Read Nothing Else

The 8 most important things to know right now.

Wilson Disease is treatable — but only if treated for life. Unlike many genetic diseases, Wilson Disease can be effectively managed with medications that remove excess copper or prevent its absorption. However, treatment must never be stopped. Discontinuing treatment, even briefly, can cause fatal liver failure.
Diagnosis is often delayed. Wilson Disease mimics many other liver and neurological conditions. The average delay between first symptoms and diagnosis is 1–2 years. If you have unexplained liver disease, movement disorders, or psychiatric symptoms between ages 5 and 50, ask your doctor about Wilson Disease.
There are three main treatment approaches. Chelation therapy (D-penicillamine or trientine) actively removes copper from the body. Zinc therapy blocks copper absorption and is mainly used for maintenance. A new agent, bis-choline tetrathiomolybdate, has completed Phase 3 trials and offers a novel mechanism.
The Leipzig scoring system confirms diagnosis. No single test is enough. Diagnosis requires combining clinical signs, lab tests (ceruloplasmin, 24-hour urine copper, liver copper), and sometimes genetic testing. A Leipzig score of 4 or more establishes the diagnosis.
Screen all first-degree relatives. Siblings of a diagnosed patient have a 25% chance of having Wilson Disease themselves. Early detection in siblings, even before symptoms appear, allows treatment to prevent organ damage entirely.
Neurological symptoms need specialized care. About 40–50% of patients present with neurological or psychiatric symptoms. Chelation therapy can initially worsen neurological symptoms in some patients. This must be discussed with a neurologist experienced in Wilson Disease.
Liver transplant cures Wilson Disease. For patients with acute liver failure or decompensated cirrhosis not responding to medical therapy, liver transplant is curative. The new liver produces functional ATP7B protein, and patients no longer need chelation therapy after transplant.
Adherence is everything. The most common cause of treatment failure and death in Wilson Disease is patients stopping their medication. Even if you feel well, you must continue treatment for life.

▼ Collapse

Understanding Wilson Disease

Wilson Disease is a rare genetic disorder in which the body cannot properly eliminate copper. Copper is an essential trace mineral obtained from food, but in Wilson Disease, a defective gene (ATP7B) prevents the liver from excreting copper into bile. Instead, copper accumulates in the liver, brain, eyes, and other organs, causing progressive damage.

Wilson Disease is autosomal recessive — meaning a person must inherit a defective copy of the ATP7B gene from both parents to develop the condition. People with only one defective copy (carriers) do not develop symptoms.

Without treatment, Wilson Disease is fatal. With treatment, most patients can live normal, full lives. The key is early diagnosis, proper medication, and lifelong adherence to therapy.

Prevalence is approximately 1 in 30,000 worldwide (clinical disease)
Approximately 9,000 people in the United States are affected
Carrier frequency is approximately 1 in 90 people
Median age at diagnosis is 12–23 years, though it can present from age 3 to over 70
Higher prevalence in certain populations: Sardinia, Japan, China, India, and Eastern Europe (up to 1 in 10,000 in some populations)
Males and females are affected equally
More than 900 different mutations in the ATP7B gene have been identified

Copper accumulation damages organs in several ways:

Liver (most common, ~40–50% of presentations): Ranges from asymptomatic elevation of liver enzymes to fatty liver, chronic hepatitis, cirrhosis, and acute liver failure. The liver is always affected, even when neurological symptoms predominate.
Brain (~35–50% of presentations): Copper deposits in the basal ganglia and other brain regions cause movement disorders (tremor, dystonia, difficulty walking, slurred speech), psychiatric symptoms (depression, anxiety, personality changes, psychosis), and cognitive decline.
Eyes: Kayser-Fleischer rings — brownish-green copper deposits in the cornea visible on slit-lamp examination. Present in 95% of patients with neurological Wilson Disease but only ~50% of those with purely hepatic disease.
Blood: Coombs-negative hemolytic anemia (copper damages red blood cells). Often an early sign that precedes other symptoms.
Kidneys: Renal tubular dysfunction (loss of amino acids, glucose, and phosphate in urine).
Bones and joints: Premature osteoporosis, arthritis, and joint problems.
Heart: Rarely, cardiomyopathy.

The most important concept in this guide: Wilson Disease is one of the few genetic diseases that is highly treatable. Diagnosed early and treated consistently, patients can prevent organ damage and live normal lives. The challenge is getting diagnosed in the first place and maintaining lifelong treatment adherence.

Key Breakthroughs in Wilson Disease

While Wilson Disease was first described in 1912, the major treatment advances have unfolded over decades:

INVESTIGATIONAL Bis-choline tetrathiomolybdate represents a fundamentally new approach to Wilson Disease. Unlike chelators that remove copper through urine, tetrathiomolybdate works by forming a tripartite complex with copper and albumin in the blood, rendering copper non-toxic and promoting its biliary excretion. In the FoCus Phase 3 trial, it demonstrated non-inferiority to standard chelation and showed advantages in neurological outcomes, with fewer patients experiencing early neurological worsening. It is now being developed by Monopar Therapeutics (which acquired it from Alexion/AstraZeneca), which has said it plans to submit an FDA application around mid-2026 — it is not yet FDA-approved or under FDA review. If approved, it would be the first new mechanism of action for Wilson Disease in decades.

INVESTIGATIONAL Gene therapy aims to deliver a functional copy of the ATP7B gene directly to liver cells using adeno-associated virus (AAV) vectors. If successful, this could be a one-time cure, eliminating the need for lifelong medication. Ultragenyx (UX701, in the pivotal Cyprus2+ trial, NCT04884815) and Vivet Therapeutics/Pfizer (VTX-801, GATEWAY trial, NCT04537377) have run early-phase trials; the VTX-801 GATEWAY trial stopped recruitment in 2024 and is now in long-term follow-up only. Results are preliminary but have shown dose-dependent reductions in copper markers. Both remain investigational; significant challenges include durability of expression and immune responses to the AAV vector.

FDA-APPROVED Cuvrior (trientine tetrahydrochloride, approved by FDA in 2022) is a new salt form of trientine that does not require refrigeration, has improved stability, and offers more predictable absorption compared to the older trientine dihydrochloride (Syprine). It was the first new Wilson disease drug approved in the US in roughly 50 years (penicillamine, Syprine, and zinc came earlier). Its FDA indication is specifically for adults with stable Wilson disease who are already de-coppered and tolerant of penicillamine — i.e., a maintenance option rather than initial de-coppering.

IN DEVELOPMENT Traditional newborn screening for Wilson Disease has been limited because ceruloplasmin levels are physiologically low in all neonates. However, advances in dried blood spot ATP7B protein quantification and targeted genetic screening panels are being studied. Pilot programs in select regions are evaluating the feasibility of adding Wilson Disease to newborn screening panels. Early detection would allow pre-symptomatic treatment and prevent all organ damage.

The Leipzig scoring system, developed by an international panel at the 8th International Meeting on Wilson Disease in 2001 and updated since, provides a standardized, point-based framework for diagnosing Wilson Disease. It combines clinical, biochemical, and genetic criteria into a single score. A score of 4 or more establishes the diagnosis. This system has been adopted globally and is recommended by both AASLD and EASL guidelines.

Diagnosis: The Tests You Need

No single test can diagnose Wilson Disease. The diagnosis requires a combination of clinical findings, laboratory tests, and sometimes genetic testing. Because Wilson Disease is rare and mimics many other conditions, diagnosis is often delayed.

Ceruloplasmin is a copper-carrying protein made by the liver. In Wilson Disease, ceruloplasmin levels are typically low (below 20 mg/dL). However, this test alone is not diagnostic:

About 5–15% of Wilson Disease patients have normal ceruloplasmin
Ceruloplasmin can be falsely low in liver failure from any cause, protein-losing conditions, and in heterozygous carriers
Ceruloplasmin can be falsely elevated during infection, inflammation, pregnancy, and estrogen use (it is an acute-phase reactant)

A low ceruloplasmin raises suspicion but does not confirm the diagnosis.

This is one of the most important diagnostic tests. In Wilson Disease, 24-hour urine copper is elevated, typically above 40 mcg/day (the AASLD 2023 guidance uses >40 mcg/day as suggestive, not the older >100 mcg threshold). Values above 100 mcg/day are strongly suggestive. During D-penicillamine challenge testing in children, values above 1,600 mcg/day are diagnostic.

Collection must be done correctly: Use a copper-free container. Incomplete collection gives falsely low results. Always verify with creatinine that the collection is complete.

An ophthalmologist performs a slit-lamp examination to look for Kayser-Fleischer (KF) rings — brownish-green copper deposits in Descemet’s membrane of the cornea. These are:

Present in approximately 95% of patients with neurological Wilson Disease
Present in only about 50% of patients with purely hepatic Wilson Disease
Rarely seen with the naked eye — slit-lamp examination is required
Not entirely specific to Wilson Disease (can occasionally occur in chronic cholestatic liver disease)

KF rings typically fade and disappear with successful treatment, making them a useful marker of treatment response.

Liver biopsy with quantitative copper measurement remains the gold standard for diagnosis when other tests are inconclusive. Hepatic copper content above 250 mcg/g dry weight is strongly supportive of Wilson Disease (normal is 15–55 mcg/g). However:

Copper distribution in the liver can be uneven, especially in cirrhosis, leading to sampling error
Values between 75 and 250 mcg/g can occur in other cholestatic liver diseases
A liver biopsy also provides important information about the degree of liver damage (fibrosis, cirrhosis)

Non-ceruloplasmin-bound copper (NCC, also called “free copper”) is calculated by subtracting ceruloplasmin-bound copper from total serum copper. In untreated Wilson Disease, NCC is typically elevated (above 15 mcg/dL). Direct measurement of NCC (exchangeable copper, CuEXC, or relative exchangeable copper, REC) is a newer, more accurate approach being adopted at specialized centers. REC above 18.5% has shown excellent diagnostic accuracy.

Brain MRI is recommended for all Wilson Disease patients, even those without neurological symptoms. Characteristic findings include signal abnormalities in the basal ganglia (putamen, caudate, globus pallidus), thalamus, brainstem, and cerebellum. The “face of the giant panda” sign in the midbrain is considered classic but is actually uncommon. MRI findings may be present before neurological symptoms develop and can help guide treatment decisions.

Key question for your doctor: “Have you tested my ceruloplasmin, 24-hour urine copper, and ordered a slit-lamp examination? Have you calculated my Leipzig score? Should we pursue genetic testing or liver biopsy to confirm the diagnosis?”

Leipzig Scoring System — How Diagnosis Is Confirmed

The Leipzig scoring system is the internationally accepted diagnostic framework for Wilson Disease. It assigns points based on clinical, laboratory, and genetic findings. A total score of 4 or more establishes the diagnosis.

Feature	Finding	Points
Kayser-Fleischer rings	Present / Absent	+2 / 0
Neuropsychiatric symptoms	Suggestive of Wilson / Absent	+2 / 0
Coombs-negative hemolytic anemia	Present / Absent	+1 / 0
Serum ceruloplasmin	<10 mg/dL / 10–20 mg/dL / Normal (>20)	+2 / +1 / 0
24-hour urine copper	>2× ULN / 1–2× ULN / Normal	+2 / +1 / 0
Hepatic copper content	>250 mcg/g / 50–250 mcg/g / Normal (<50) / Rhodanine-positive	+2 / +1 / −1 / +1
ATP7B mutation analysis	2 pathogenic mutations / 1 mutation / None	+4 / +1 / 0

Interpretation: Score ≥4 = Diagnosis established. Score 3 = Possible, needs more investigation. Score ≤2 = Unlikely.

Genetic Testing & Family Screening

Wilson Disease is caused by mutations in the ATP7B gene on chromosome 13. Over 900 different mutations have been identified. Genetic testing is important for confirming diagnosis and for screening family members.

When clinical and laboratory findings are inconclusive (Leipzig score 2–3)
For screening all first-degree relatives (siblings, parents, children) of a confirmed patient
For family planning and genetic counseling
To identify the specific mutations in the proband (first diagnosed family member), enabling faster, cheaper targeted testing of relatives

European populations: H1069Q is the most common mutation (~35–65% of alleles in Northern/Central Europe)
East Asian populations: R778L is the most common mutation (~30–50% of alleles in China, Japan, Korea)
Indian subcontinent: Multiple mutations; no single dominant allele
Sardinia: −441/−427del founder mutation

Most patients are compound heterozygotes — they carry two different ATP7B mutations, one from each parent. Full gene sequencing is often needed.

Siblings of a diagnosed patient have a 25% chance of having Wilson Disease. All first-degree relatives should be tested with:

Serum ceruloplasmin
24-hour urine copper
Liver function tests
Slit-lamp examination
Targeted genetic testing for the mutations identified in the proband (faster and cheaper than full sequencing)

Presymptomatic siblings found to have Wilson Disease must start treatment immediately, even if they feel perfectly well. Early treatment prevents all organ damage.

What is my Leipzig score, and which tests contributed to it?
Should I have genetic testing for ATP7B mutations?
Have all my first-degree relatives been screened?
Do I need a liver biopsy to measure hepatic copper content?
Should I have a brain MRI, even if I do not have neurological symptoms?
Is my liver disease at the stage of fibrosis or cirrhosis?
Would genetic counseling be helpful for my family?

Chelation Therapy — Removing Copper

Chelation therapy uses drugs that bind copper in the body and promote its excretion through urine. This is the primary treatment for symptomatic Wilson Disease and the initial treatment for most newly diagnosed patients.

FDA-APPROVED D-penicillamine was the first oral chelator for Wilson Disease (introduced in 1956 by John Walshe). It binds copper and promotes its excretion in urine.

Dosing: Start low (250–500 mg/day) and increase gradually over weeks to 1,000–1,500 mg/day in 2–4 divided doses. Take on an empty stomach (1 hour before or 2 hours after meals).
Pyridoxine (vitamin B6): 25 mg/day supplementation is required because D-penicillamine depletes B6.
Common side effects: Nausea, loss of taste, skin rash, mouth sores, proteinuria, bone marrow suppression (leukopenia, thrombocytopenia).
Serious side effects: Lupus-like syndrome, nephrotic syndrome, aplastic anemia, elastosis perforans serpiginosa (skin condition), myasthenia gravis-like syndrome. Up to 30% of patients discontinue due to side effects.
Neurological worsening: 10–50% of patients with neurological Wilson Disease experience initial worsening of neurological symptoms when starting D-penicillamine. This is a significant concern and a reason some experts prefer trientine for neurological cases.
Advantages: Long track record, widely available globally, lower cost (important in low- and middle-income countries).

FDA-APPROVED Trientine (triethylenetetramine) is an alternative chelator that binds copper and promotes its urinary excretion. It is generally better tolerated than D-penicillamine.

Available forms: Trientine dihydrochloride (Syprine, requires refrigeration) and trientine tetrahydrochloride (Cuvrior, FDA-approved 2022, room temperature storage, improved bioavailability).
Dosing: 750–1,500 mg/day in 2–3 divided doses, taken on an empty stomach.
Side effects: Generally fewer than D-penicillamine. Iron deficiency anemia (trientine can chelate iron), gastric irritation, rare lupus-like reactions.
Neurological worsening: Lower rate of initial neurological worsening compared to D-penicillamine, though it can still occur.
Current role: First-line alternative to D-penicillamine. AASLD 2023 considers both chelators as acceptable first-line therapy. Many experts prefer trientine for neurological Wilson Disease due to the lower risk of neurological worsening.
Limitations: Higher cost than D-penicillamine; availability varies internationally.

Critical warning: Chelation therapy must be started gradually (low dose, slowly increased) to avoid rapid mobilization of copper stores, which can worsen liver damage or neurological symptoms. Never start at full dose.

Should I start with D-penicillamine or trientine, and why?
What is the plan if I experience side effects or neurological worsening?
How quickly will you increase my dose, and what monitoring is needed during dose escalation?
Am I taking pyridoxine (B6) supplementation with D-penicillamine?
When can I transition from chelation to zinc maintenance therapy?
Am I a candidate for the newer trientine formulation (Cuvrior)?
Is there a clinical trial for bis-choline tetrathiomolybdate or gene therapy that I might be eligible for?
What dietary changes should I make regarding copper-rich foods?

Zinc Therapy — Blocking Copper Absorption

Zinc therapy works by a completely different mechanism than chelation. Zinc induces the production of metallothionein in intestinal cells, which binds dietary copper and prevents its absorption. The copper-metallothionein complex is then shed when intestinal cells are naturally replaced, effectively blocking copper uptake.

FDA-APPROVED

Dosing: 50 mg of elemental zinc three times daily (150 mg/day total). Take on an empty stomach, at least 1 hour before or 2 hours after meals. Zinc acetate is preferred because other zinc salts (gluconate, sulfate) may cause more gastric irritation.
Primary uses:
- Maintenance therapy: After initial de-coppering with chelation therapy, many patients transition to zinc for long-term maintenance
- Pre-symptomatic patients: Zinc is often used as first-line treatment for presymptomatic patients identified through family screening
- Pregnancy: Zinc is considered safer than chelation therapy during pregnancy
Advantages: Very few systemic side effects, no immune-mediated reactions, safe in pregnancy, low cost.
Disadvantages: Slower onset of action than chelation (weeks to months to achieve negative copper balance). Not recommended as sole initial therapy for symptomatic patients with significant copper overload. Gastric irritation is the main complaint (30–50% of patients).
Important: Zinc must NOT be taken at the same time as chelation therapy. Separate by at least 1–2 hours. Taking them together causes the chelator to bind the zinc instead of copper.

In Europe, zinc is more widely used as a first-line monotherapy for Wilson Disease maintenance and even for mildly symptomatic patients, particularly those identified through family screening. EASL 2012 guidelines support zinc as first-line therapy for presymptomatic and mildly hepatic patients. Some European centers use zinc monotherapy for mild neurological Wilson Disease as well, to avoid the risk of neurological worsening seen with chelation. This practice differs from the AASLD approach, which generally recommends chelation as initial therapy for all symptomatic patients.

Monitoring on Treatment

Lifelong monitoring is essential to ensure treatment is working, to detect side effects early, and to confirm adherence.

Test	Frequency	Purpose
24-hour urine copper	Every 6–12 months	On chelation: target 200–500 mcg/day (adequate chelation without over-treatment). On zinc: target <75 mcg/day
Non-ceruloplasmin-bound copper (NCC)	Every 6–12 months	Target <15 mcg/dL (ideally 5–15 mcg/dL). Over-treatment can cause copper deficiency (NCC <5)
Liver function tests (AST, ALT, bilirubin, albumin)	Every 3–6 months	Monitor liver disease stability and treatment response
Complete blood count	Every 3–6 months (more frequent with D-penicillamine)	Detect bone marrow suppression (D-penicillamine) or iron deficiency (trientine)
Urinalysis	Every 6 months	Detect proteinuria (D-penicillamine nephrotoxicity)
Neurological assessment	Every 6–12 months	Track neurological symptoms and function; consider standardized scales (UWDRS)

Over-treatment warning: Aggressive chelation can deplete copper below normal levels, causing copper deficiency. This can lead to anemia, neutropenia, and neurological problems similar to Wilson Disease itself. Monitoring NCC levels helps prevent this. The goal is adequate copper removal, not zero copper.

Neurological Wilson Disease

About 35–50% of Wilson Disease patients present with neurological or psychiatric symptoms. Managing neurological Wilson Disease requires special expertise and care.

Movement disorders: Tremor (often asymmetric, wing-beating type), dystonia (sustained abnormal postures), parkinsonism (slow movement, rigidity), chorea (involuntary jerky movements), ataxia (unsteady gait)
Speech and swallowing: Dysarthria (slurred speech), dysphagia (difficulty swallowing), drooling
Psychiatric: Depression, anxiety, personality changes, impulsivity, irritability, psychosis (rare but can be the presenting symptom)
Cognitive: Difficulty concentrating, academic decline in children and adolescents, executive function problems

10–50% of patients with neurological Wilson Disease experience worsening of neurological symptoms when chelation therapy is started. This is thought to be caused by rapid mobilization of copper from liver stores into the bloodstream and brain. In some cases, this worsening is irreversible.

Strategies to minimize this risk include:

Starting chelation at a very low dose and increasing slowly
Some experts prefer trientine over D-penicillamine for neurological cases (lower reported rate of worsening)
Adding zinc to chelation from the beginning to block ongoing copper absorption
Bis-choline tetrathiomolybdate (investigational) showed lower rates of neurological worsening compared to D-penicillamine in the FoCus trial, which is one of its potential advantages
Close neurological monitoring during the first 3–6 months of treatment

Which chelator carries the lowest risk of neurological worsening for my situation?
How will you monitor my neurological function during treatment initiation?
Should I see a movement disorder neurologist in addition to my hepatologist?
Am I a candidate for a clinical trial of bis-choline tetrathiomolybdate?
What medications can help manage my specific symptoms (tremor, dystonia, depression)?
If my neurological symptoms worsen after starting treatment, what is the plan?

Liver Disease in Wilson Disease

The liver is always affected in Wilson Disease, even when neurological symptoms are the primary presentation. Liver manifestations range from asymptomatic enzyme elevations to acute liver failure requiring emergency transplant.

Asymptomatic liver enzyme elevation: Often discovered incidentally on routine bloodwork. Important not to dismiss this in young patients.
Fatty liver (steatosis): Can mimic non-alcoholic fatty liver disease (NAFLD).
Chronic hepatitis: Mimics autoimmune hepatitis. Wilson Disease should be excluded in any young patient diagnosed with autoimmune hepatitis.
Cirrhosis: Can develop silently over years. Compensated cirrhosis may respond to medical therapy. Decompensated cirrhosis may require transplant.
Acute liver failure (fulminant Wilson Disease): A medical emergency. Characterized by rapid-onset jaundice, coagulopathy, hemolytic anemia (Coombs-negative), renal failure, and very low alkaline phosphatase. Mortality without transplant approaches 100%. The revised Wilson Prognostic Index (New Wilson Index) helps predict which patients will need transplant.

Dietary copper restriction is a supportive measure, not a primary treatment. However, patients should avoid foods very high in copper, especially during the initial de-coppering phase:

Avoid: Liver and organ meats, shellfish (especially oysters, lobster, crab), chocolate, nuts (especially cashews), mushrooms, soy products, and dried fruit
Check your water: If your home has copper plumbing and water copper levels exceed 0.1 mg/L, consider a water filter or alternative water source
Dietary restriction alone is never sufficient to treat Wilson Disease — medication is always required

Liver Transplant

Liver transplant is curative for Wilson Disease. The new liver produces functional ATP7B protein, normalizing copper metabolism. After successful transplant, patients no longer need chelation or zinc therapy.

Acute liver failure (fulminant Wilson Disease): Emergency transplant is required. Without it, mortality approaches 100%. The New Wilson Index (NWI, scoring bilirubin, INR, AST, WBC, albumin) helps predict which patients with acute presentation will need transplant (NWI ≥11 predicts >95% mortality without transplant).
Decompensated cirrhosis not responding to medical therapy: Patients with progressive liver failure despite 3–6 months of adequate chelation therapy should be referred for transplant evaluation.
Non-compliance-related liver failure: Patients who have stopped treatment and developed severe liver failure. This is tragically common in adolescents and young adults.

Liver transplant for Wilson Disease has excellent outcomes:

5-year patient survival: 85–90% (among the best outcomes for any liver transplant indication)
Copper metabolism normalizes post-transplant — chelation therapy is no longer needed
Kayser-Fleischer rings gradually fade and disappear after transplant
Neurological symptoms may stabilize or improve after transplant, though improvement is not guaranteed, especially for long-standing neurological disease
Living-donor transplant is an option; carriers (heterozygous donors) can safely donate — their one functional ATP7B copy produces enough functional protein

Liver transplant for patients whose primary indication is severe, treatment-resistant neurological Wilson Disease (without liver failure) remains controversial. Some case reports show neurological improvement after transplant, but others show no benefit or worsening. Most transplant guidelines do not recommend transplant solely for neurological Wilson Disease. However, individual cases should be discussed at experienced Wilson Disease centers.

Is my liver disease responding adequately to chelation therapy?
What is my MELD score, and should I be listed for transplant?
If I have acute liver failure, is emergency transplant available at this center?
Would a living-donor transplant be an option for me?
Can a carrier (heterozygous family member) safely donate?
Will my neurological symptoms improve after transplant?
What is the expected recovery and immunosuppression plan?

Pregnancy & Special Populations

Women with Wilson Disease can have successful pregnancies, but treatment must continue throughout:

Zinc is generally considered the safest option during pregnancy and is recommended by most experts
D-penicillamine: Teratogenic in animal studies; if continued during pregnancy, the dose should be reduced to the minimum effective dose. Some experts recommend switching to zinc before conception.
Trientine: Limited pregnancy data but generally considered safer than D-penicillamine. Dose reduction is recommended.
Never stop treatment entirely during pregnancy. Untreated Wilson Disease during pregnancy can cause fulminant liver failure.
Breastfeeding is generally considered safe with zinc therapy. Data on chelators during breastfeeding are limited.

Wilson Disease can present in children as young as 3 years old. Pediatric considerations include:

Any child with unexplained liver disease should be screened for Wilson Disease
D-penicillamine dosing in children: 20 mg/kg/day in 2–3 divided doses
Trientine dosing in children: 20 mg/kg/day in 2–3 divided doses
Zinc dosing in children: body weight-based (25 mg elemental zinc 2–3 times daily for children under 50 kg)
Adolescents are at particularly high risk for non-adherence. Close monitoring and family support are essential.

class="content-section" data-stage="advanced">

Clinical Trials — Finding and Enrolling

Several important clinical trials are ongoing or recently completed for Wilson Disease, addressing both new treatment approaches and potential cures.

Trial / Program	Agent	Population	NCT Number
FoCus (Phase 3)	Bis-choline tetrathiomolybdate (ALXN1840)	Adult Wilson Disease	NCT03403205
FoCus long-term extension	Bis-choline tetrathiomolybdate long-term (up to 60-mo extension of FoCus)	Completers from FoCus	NCT03403205
Cyprus2+ — UX701 (Phase 1/2/3)	AAV gene therapy (Ultragenyx)	Adult Wilson Disease on stable therapy	NCT04884815
GATEWAY — VTX-801 (Phase 1/2)	AAV gene therapy (Vivet/Pfizer) — recruitment stopped (2024); long-term follow-up only	Adult Wilson Disease	NCT04537377
Cuvrior (Phase 3)	Trientine tetrahydrochloride	Adults tolerant of penicillamine	NCT03539952

NCT numbers verified against ClinicalTrials.gov. Always confirm current enrollment status directly.

ClinicalTrials.gov (clinicaltrials.gov): Search for “Wilson Disease” and filter by status (recruiting) and location
Wilson Disease Association (WDA): wilsondisease.org — maintains trial listings and can help connect patients with researchers
Rare Diseases Clinical Research Network (RDCRN): NIH-funded network studying rare diseases including Wilson Disease
Your hepatology center: Academic centers treating Wilson Disease often run or participate in trials not widely advertised
European Reference Network for Hepatological Diseases (ERN RARE-LIVER): Coordinates Wilson Disease research across Europe

International Access & Regulatory Landscape

Treatment availability for Wilson Disease varies significantly by country, which is especially important because this disease has higher prevalence in certain regions.

Drug	US FDA	EMA (Europe)	Other Regions	Notes
D-penicillamine	Approved (1970)	Approved	Widely available globally	First-line in many LMIC due to lower cost; generic available
Trientine dihydrochloride (Syprine)	Approved (1985)	Approved (limited countries)	Variable availability	Requires refrigeration; availability varies significantly outside US/Europe
Trientine tetrahydrochloride	Approved 2022 (Cuvrior)	Approved Sep 2017 (Cuprior)	Limited	Room-temperature, improved formulation. EU brand = Cuprior (penicillamine-intolerant); US brand = Cuvrior (stable, de-coppered, penicillamine-tolerant)
Zinc acetate (Galzin)	Approved (1997)	Approved	Widely available	Zinc salts (gluconate, sulfate) are available over the counter globally as alternatives
Bis-choline tetrathiomolybdate (ALXN1840)	Not approved (investigational)	Not approved (investigational)	Not available	Phase 3 (FoCus) completed; now developed by Monopar; FDA application planned ~mid-2026 (not yet submitted)

AASLD (US): 2023 Practice Guidance on Wilson Disease (Schilsky et al., Hepatology 2023) — most current comprehensive guideline
EASL (Europe): 2012 Clinical Practice Guidelines (update pending) — important for European practice patterns
ESPGHAN (European pediatric): Guidelines for pediatric Wilson Disease management
NICE (UK): Technology appraisals for Wilson Disease treatments
Wilson Disease Association (WDA, US): wilsondisease.org
EuroWilson: European network of Wilson Disease centers
JSPH (Japan Society for Pediatric Hepatology): Japanese guidelines for Wilson Disease
Indian National Association for Study of the Liver (INASL): Guidelines addressing high prevalence and specific mutations in India

Failed & De-Adopted Therapies

Understanding what has been tried and did not work, or was abandoned, helps evaluate new options.

REFORMULATED The original ammonium salt of tetrathiomolybdate showed promise in early clinical trials for neurological Wilson Disease but had formulation problems (instability, variable bioavailability, liver toxicity including transaminase elevations). It was never approved as a commercial product. The reformulated bis-choline salt (ALXN1840/WTX101) was developed to overcome these stability issues and is the version that completed Phase 3 trials.

DE-ADOPTED Before oral chelators were available, BAL (British Anti-Lewisite, dimercaprol) was used as an intramuscular copper chelator. It was painful, poorly tolerated, and required injection. It has been entirely replaced by oral chelators and is no longer used for Wilson Disease, except in extraordinarily rare emergency situations where no oral therapy is feasible.

CONTESTED While zinc is widely accepted for maintenance therapy and presymptomatic patients, its use as sole initial therapy for patients with significant hepatic or neurological Wilson Disease remains controversial. Some studies have reported treatment failures and hepatic decompensation when zinc was used as monotherapy in patients with active symptomatic disease. AASLD 2023 generally recommends chelation as initial therapy for symptomatic patients, with zinc reserved for maintenance or combination use.

NOT RECOMMENDED Liver transplant solely for neurological Wilson Disease (without liver failure) has been attempted in case series. Results are mixed — some patients showed neurological improvement, but others showed no benefit or even worsening. The risks of transplant surgery and lifelong immunosuppression are not justified by the current evidence for neurological-only indications. This remains an area of active debate.

Why this matters: If someone suggests an approach you haven’t heard of, you now have context. Always ask your hepatologist: “What is the evidence for this approach in Wilson Disease, and is it recommended by AASLD or EASL guidelines?”

class="content-section" data-stage="resources">

Specialty Centers

Wilson Disease is rare enough that many general gastroenterologists and neurologists have limited experience with it. Care at, or at least a second opinion from, a center experienced in Wilson Disease management can significantly improve outcomes.

No endorsement. Listing a center here does not constitute an endorsement or recommendation. Trouvera has no financial relationship with any medical center listed unless explicitly disclosed. Patients should evaluate centers based on their own needs and in consultation with their medical team.

When to seek specialized Wilson Disease care:

Newly diagnosed Wilson Disease — for treatment initiation and monitoring plan
Neurological Wilson Disease — requires hepatologist AND movement disorder neurologist coordination
Acute liver failure — emergency referral to a transplant center
Treatment intolerance or failure — need for alternative agents or clinical trial access
Pregnancy planning — medication adjustment guidance
Pediatric cases — dosing and monitoring differ from adults

University of Utah Health — Hepatology Program

Academic medical center with hepatology expertise and liver transplant program

Location: 30 N 1900 E, Salt Lake City, UT 84132
Phone: 801-581-2121
Programs: Hepatology clinic with experience in metabolic liver diseases including Wilson Disease. Liver transplant program for decompensated cirrhosis and acute liver failure. ARUP Laboratories provides genetic testing for ATP7B mutations and copper studies.

Huntsman Cancer Institute (HCI) — University of Utah

Location: 2000 Circle of Hope Dr, Salt Lake City, UT 84112
Phone: 801-585-0303
Programs: While primarily an oncology center, HCI’s affiliation with the University of Utah Health system provides access to comprehensive diagnostic services including ARUP molecular diagnostics and the broader hepatology team.

Intermountain Health — Liver Program

Location: Intermountain Medical Center, 5121 S Cottonwood St, Murray, UT 84107
Phone: 801-442-2000
Programs: Liver transplant program, hepatology services, and community-based care across Utah and the Intermountain West.

Primary Children’s Hospital — Pediatric Hepatology

Location: 100 N Mario Capecchi Dr, Salt Lake City, UT 84113
Phone: 801-662-1000
Programs: Pediatric hepatology with experience in Wilson Disease diagnosis and management in children and adolescents. Part of the University of Utah Health system.

How to choose. University of Utah Health = academic hepatology with liver transplant, ARUP diagnostics, and genetic testing capabilities. Intermountain Health = liver transplant-capable community health system. Primary Children’s = pediatric cases.

Information verified June 2026. Availability changes — confirm with each institution directly.

Yale New Haven Hospital — Wilson Disease Center of Excellence

Location: New Haven, CT · Phone: 203-785-4138
Led by Dr. Michael Schilsky (lead author of AASLD 2023 Wilson Disease Guidance). One of the foremost Wilson Disease programs in the world. Clinical trials, transplant program, comprehensive diagnostic workup.

University of Michigan — Hepatology

Location: Ann Arbor, MI · Phone: 734-936-4000
Wilson Disease expertise within a large hepatology program. Clinical trials and liver transplant center.

Mount Sinai Health System — Liver Diseases

Location: New York, NY · Phone: 212-241-6500
Large hepatology division with Wilson Disease experience. Liver transplant program.

Cleveland Clinic — Hepatology

Location: Cleveland, OH · Phone: 216-444-6568
Digestive Disease and Surgery Institute with hepatology and liver transplant.

Children’s Hospital Colorado — Pediatric Hepatology

Location: Aurora, CO · Phone: 720-777-1234
Pediatric liver center with experience in Wilson Disease. Part of the University of Colorado system.

Mayo Clinic Rochester

Location: Rochester, MN · Phone: 507-538-3270
Comprehensive hepatology and liver transplant program with metabolic liver disease expertise.

VA Hepatology Care

The VA system provides hepatology care through its network of medical centers. For Wilson Disease requiring specialized expertise or transplant, the VA typically partners with academic centers through community care arrangements. Veterans should ask their VA provider about:

Referral to an academic hepatology center for Wilson Disease evaluation
Community care authorization for genetic testing at ARUP or comparable laboratory
Clinical trial access through VA-academic partnerships

George E. Wahlen VA Medical Center, Salt Lake City: 801-582-1565
VA Community Care: 1-877-881-7618

Toronto General Hospital (UHN) — Liver Centre

Location: 200 Elizabeth Street, Toronto, ON M5G 2C4
Phone: 416-340-3111
Programs: One of Canada’s largest liver transplant programs. Wilson Disease expertise within the hepatology division.

The Hospital for Sick Children (SickKids), Toronto

Location: 555 University Avenue, Toronto, ON M5G 1X8
Phone: 416-813-1500
Programs: Pediatric hepatology center with Wilson Disease experience. Genetic testing and family screening.

BC Children’s Hospital — Hepatology

Location: Vancouver, BC
Phone: 604-875-2345
Programs: Pediatric hepatology including metabolic liver diseases.

Canadian Liver Foundation: liver.ca
Canadian Organization for Rare Disorders: 1-877-302-7273

International Centers of Excellence for Wilson Disease

Heidelberg University Hospital, Germany: Major European Wilson Disease center; EuroWilson network participant
Institute of Psychiatry and Neurology, Warsaw, Poland: Largest Wilson Disease cohort globally; specializes in neurological Wilson Disease
King’s College Hospital, London, UK: Leading liver transplant center; extensive Wilson Disease acute liver failure experience
Hôpital Beaujon (APHP), Clichy, France: French reference center for Wilson Disease
University of Cagliari, Sardinia, Italy: High-prevalence population; genetic research leader
Institute of Liver and Biliary Sciences (ILBS), New Delhi, India: Major center for Wilson Disease in South Asia
National Center for Child Health and Development, Tokyo, Japan: Japanese Wilson Disease registry and clinical trials

Caregiver Guidance

Caring for someone with Wilson Disease presents unique challenges, particularly around medication adherence, neurological symptom management, and the psychological impact of a lifelong diagnosis often made in adolescence or young adulthood.

The most common cause of Wilson Disease-related death is non-adherence. Patients who stop taking medication can develop fulminant liver failure within weeks to months.
Adolescents and young adults are at highest risk for stopping medication. They may feel well, resent the burden of a chronic illness, or face challenges taking medications on an empty stomach multiple times daily.
Practical tips: Set phone alarms for medication times. Use pill organizers. Connect medication with daily routines. Discuss adherence openly and non-judgmentally at every clinic visit.
Monitor urine copper levels as an objective measure of adherence (rising levels suggest missed doses).

Neurological recovery can be very slow — improvement may take months to years. Set realistic expectations.
Speech therapy can help with dysarthria and dysphagia.
Physical therapy and occupational therapy are important for movement disorders.
Psychiatric symptoms (depression, anxiety, personality changes) are part of the disease, not a character flaw. Professional psychiatric care should be part of the treatment team.

Wilson Disease Association (WDA): wilsondisease.org — patient education, support groups, and annual conferences
National Organization for Rare Disorders (NORD): rarediseases.org — rare disease patient assistance
Global Genes: globalgenes.org — rare disease advocacy and support
Connecting with other Wilson Disease families through WDA support groups can be invaluable, particularly for parents of newly diagnosed children

Glossary

ATP7B: The gene mutated in Wilson Disease. Encodes a copper-transporting ATPase in the liver. Over 900 mutations identified.
Autosomal recessive: A pattern of inheritance where both copies of a gene must be mutated to cause disease. Each parent carries one mutant copy.
Ceruloplasmin: A copper-carrying protein made by the liver. Typically low in Wilson Disease but not always diagnostic alone.
Chelation therapy: Treatment using drugs (D-penicillamine, trientine) that bind copper and promote its excretion in urine.
Compound heterozygote: A person carrying two different mutations in the same gene, one from each parent. Most Wilson Disease patients are compound heterozygotes.
Copper deficiency: Over-treatment with chelation can deplete copper below normal levels, causing anemia, neutropenia, and neurological problems.
Cuvrior: Brand name for trientine tetrahydrochloride, a newer formulation of trientine approved by FDA in 2022.
D-penicillamine: The first oral copper chelator. Effective but has significant side effects in up to 30% of patients.
Dystonia: Sustained or repetitive muscle contractions causing abnormal postures. A common neurological symptom in Wilson Disease.
Fulminant liver failure: Acute, severe liver failure developing rapidly. In Wilson Disease, this is a medical emergency requiring transplant.
Galzin: Brand name for zinc acetate, used for Wilson Disease maintenance therapy.
Kayser-Fleischer rings: Brownish-green copper deposits in the cornea, visible by slit-lamp exam. Present in ~95% of neurological Wilson Disease.
Leipzig score: A point-based scoring system combining clinical, laboratory, and genetic criteria to diagnose Wilson Disease. Score ≥4 = diagnosis established.
Metallothionein: A protein induced by zinc that binds copper in intestinal cells, preventing its absorption. The mechanism of zinc therapy.
NCC (non-ceruloplasmin-bound copper): The “free copper” in the blood not bound to ceruloplasmin. Elevated in untreated Wilson Disease; used to monitor treatment.
New Wilson Index (NWI): A prognostic scoring system for acute Wilson Disease presentations. NWI ≥11 predicts need for transplant.
Syprine: Brand name for trientine dihydrochloride, a copper chelator requiring refrigeration.
Tetrathiomolybdate: A compound that forms complexes with copper and albumin, rendering copper non-toxic. Bis-choline tetrathiomolybdate (ALXN1840) is in clinical trials.
Trientine: A copper chelator (triethylenetetramine). Available as dihydrochloride (Syprine) and tetrahydrochloride (Cuvrior).

Sources and Further Reading

This guide draws on published medical literature, clinical trial records, and the work of physicians treating Wilson Disease across multiple countries. Key sources are listed below.

Primary Resources

PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
ClinicalTrials.gov (clinicaltrials.gov) — Authoritative registry of clinical trials
Wilson Disease Association (WDA) (wilsondisease.org) — Patient education, support, clinical trial information
National Organization for Rare Disorders (NORD) (rarediseases.org) — Rare disease resources and patient assistance
GeneReviews — Wilson Disease (GeneReviews) — Expert-authored, peer-reviewed genetic disease information
American Liver Foundation (liverfoundation.org) — Liver disease education and support

Key Guideline and Trial References

AASLD 2023: Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: 2023 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2023;78(4):1428–1455.
EASL 2012: European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Wilson’s disease. J Hepatol. 2012;56(3):671–685.
Leipzig Score: Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23(3):139–142.
FoCus Trial: Weiss KH, Thurik F, Guttman DF, et al. Efficacy and safety of bis-choline tetrathiomolybdate in patients with Wilson disease: results from the FoCus trial. Lancet Gastroenterol Hepatol. (NCT03403205)
Cuvrior Approval: Trientine tetrahydrochloride for Wilson Disease. (NCT03539952)
Gene Therapy: UX701 (Ultragenyx, Cyprus2+) for Wilson Disease (NCT04884815); VTX-801 (Vivet/Pfizer, GATEWAY) (NCT04537377).
ELN 2017 (Wilson Disease-specific): Weiss KH, Stremmel W. Clinical considerations for an effective medical therapy in Wilson disease. Ann N Y Acad Sci. 2014;1315:81–85.

External links notice: Links to government agencies, academic institutions, and private organizations are provided for informational convenience. Linking does not constitute endorsement by Trouvera, and we cannot attest to the accuracy of external content. You will be subject to the destination site’s privacy policy when you leave this site.

Key Search Terms for ClinicalTrials.gov and PubMed

“Wilson disease D-penicillamine trientine”
“Wilson disease zinc acetate maintenance”
“Wilson disease Leipzig score diagnosis”
“ATP7B mutation Wilson disease”
“Wilson disease liver transplant outcomes”
“Wilson disease neurological worsening chelation”
“Wilson disease pregnancy management”

“bis-choline tetrathiomolybdate Wilson disease FoCus trial”
“gene therapy AAV Wilson disease ATP7B”
“UX701 Ultragenyx Wilson disease”
“VTX-801 Wilson disease gene therapy”
“newborn screening Wilson disease”
“exchangeable copper REC Wilson disease diagnosis”

A practical test for any online claim: If a website is making a claim about Wilson Disease treatment that does not appear anywhere in PubMed or AASLD/EASL guidelines, that should be a significant warning sign.

What This Guide Does Not Know

An honest guide names its own limits:

This guide cannot diagnose or treat anyone. It does not know your ATP7B mutations, copper levels, liver status, neurological function, or personal preferences. Only your medical team can build an actual plan.
Wilson Disease management is evolving. Gene therapy trials, new copper-lowering agents, and improved diagnostic methods are actively being studied. Every time-sensitive fact should be re-verified with your team, on FDA.gov, and on ClinicalTrials.gov.
Drug approvals and availability vary by country. This guide focuses primarily on FDA-approved therapies. Access differs in Europe, Asia, and other regions.
Individual outcomes cannot be predicted. Two patients with the same ATP7B mutations can have very different disease courses. Genotype-phenotype correlations remain imperfect.
Adherence determines outcomes more than any other factor. The best treatment plan in the world fails if the medication is not taken consistently.

A final word. Wilson Disease is a rare diagnosis, and hearing it for the first time can be frightening. But this is one of the most treatable genetic diseases in medicine. Patients diagnosed early and treated consistently can expect to live normal, full lives. The medications work. The monitoring works. The key is never stopping. Get to a hepatologist experienced in Wilson Disease. Get your family screened. Take your medication every day. You are not alone — the Wilson Disease Association and rare disease communities are excellent sources of support and connection.